KYNB (KYNB)
Market Closed
7 Aug, 20:00
XMEX XMEX Primary MX$
127. 90
0
0%
MX$
478.49M Market Cap
- P/E Ratio
- Div Yield
5 Volume
- Eps
MX$ 127.9
Previous Close Want to track KYNB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
KYNB closed Friday higher at MX$127.9, an increase of 0% from Thursday's close, completing a monthly increase of 7.9325% or MX$9.4. Over the past 12 months, KYNB stock lost -17.4839%.
KYNB is not paying dividends to its shareholders.
KYNB has completed 1 stock splits, with the recent split occurring on Jun 17, 2025.
The company's stock is traded on one exchange.
KYNB Chart
KYNB (KYNB) FAQ
What is the stock price today?
The current price is MX$127.90.
On which exchange is it traded?
KYNB is listed on XMEX.
What is its stock symbol?
The ticker symbol is KYNB.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 478.49M.
Has KYNB ever had a stock split?
KYNB had 1 splits and the recent split was on Jun 17, 2025.
KYNB Profile
| - Industry | - Sector | Mr. Thane Wettig CEO | XMEX Exchange | - ISIN |
| United States Country | 34 Employees | - Last Dividend | 17 Jun 2025 Last Split | - IPO Date |
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Contact Information
Address: 350 Bay Street
Phone: 415 978 1200
Website: https://www.kyntrabio.com
